Histopathological analysis of mucinous breast cancer subtypes and comparison with invasive carcinoma of no special type

Mucinous breast cancer (MBC) is a rare histological type of breast cancer characterized primarily by mucin's production and extracellular presence. MBC is usually associated with a better prognosis than other invasive breast neoplasms. Because of the low prevalence, MBC biology is not well understood. The aim of the present study was to introduce the last 2-year experience regarding MBC pathological diagnostics in our clinical center and comparison of the obtained data with invasive breast carcinoma of no special type (NST) comprising the most common invasive breast cancer. We identified 24 MBC cases representing 3.09% of all 766 invasive breast cancers, including 15 cases of pure type and 9 mixed MBCs. The median MBC patients' age at presentation was 65.5 years. Compared to NST, MBC presented a higher T stage with a statistically larger tumor median size, although lower regional lymph node involvement, tumor histological grade and TNM stage. MBC is a rare type of breast cancer, accounting for about 4% of all diagnosed breast cancers. Our findings are consistent with those published in recent years and show significant differences between MBC and NST cancer patients and also highlight differences between pure and mixed MBC, emphasizing the essence of their differentiation. MBC is associated with a better long-term prognosis than NST and is characterized by the less aggressive biological behavior expressed through favorable clinicopathologic features in terms of tumor grade, regional lymph node involvement and hormone receptor status.

Histopathological Analysis of Mucinous Breast Cancer Subtypes and Comparison with Invasive Carcinoma of no Special Type.

BackgroundMucinous breast cancer (MBC) is a rare histological type of breast cancer characterized primarily by the production and extracellular presence of mucin and it is usually associated with a better prognosis than other invasive breast neoplasms. Because of the low prevalence, MBC biology is not well understood. MethodsThe aim of the present study was to introduce the last 2-year experience regarding MBC pathological diagnostics in our clinical center and comparison of the obtained data with invasive breast carcinoma of no special type (NST) comprising the most common invasive breast cancer. ResultsWe identified 24 MBC cases representing 3.09% of all 766 invasive breast cancers, including 15 cases of pure type and 9 mixed MBCs. The median MBC patients’ age at presentation was 65.5 years. In comparison to NST, MBC presented a higher T stage with a statistically larger tumor median size, although lower regional lymph node involvement, tumor histological grade and TNM stage. ConclusionMBC is a rare type of breast cancer accounting for about 4% of all diagnosed breast cancers. Our findings are consistent with those published in recent years and show significant differences between MBC and NST cancer patients and also highlight differences between pure and mixed MBC emphasizing the essence of their differentiation. MBC is associated with a better long-term prognosis than NST and is characterized by the less aggressive biological behavior expressed through favorable clinicopathologic features in terms of tumor grade, regional lymph node involvement and hormone receptor status.

Prognostic Factors of Lymph Nodes in Colorectal Carcinoma

Background/Aims. The aim of this study was to establish whether, and to what extent, preand intraoperatively detected characteristics (demographic, anamnestic and laboratory data) and tumor characteristics can be used in the assessment of regional lymph node involvement in patients with colorectal carcinoma. The assessment also included the number of lymph nodes involved in patients with positive lymph nodes. Considering that the number of obtained lymph nodes is resected specimens, assessment parameters also included the percentage of the involved lymph nodes within the total population of lymph nodes. Methodology. From 2010-2019, 46 patients with carcinoma of the rectum and sigmoid colon were studied, with a total number of 736 lymph nodes evaluated. Out of the total number of lymph nodes, 577 (78.4%) were benign and 159 (21.6%), malignant. Data were analyzed by multi-variant statistical methods: discriminant analysis and multiple regression. Results. For this patient group, we evaluated the following potentially predictive factors for lymph node involvement: age; serum hemoglobin, albumin and alkaline phosphatase levels; weight loss; and the primary tumor localization characteristics: histological type, macroscopic growth pattern and depth of tumor invasion of the bowel wall. We found that there was no difference in the prediction of regional lymph node involvement between analysis of the aforementioned parameters and analysis of the isolated discriminators only. Conclusion. A predictability likelihood of 83.78% greatly surpasses the acceptable error tolerance level of 5%. Correlation of demographic, anamnestic and laboratory data about the patient and the characteristics of the primary tumor cannot be used in distinguishing malignant lymph nodes from benign ones. These data cannot be the basis for exact intraoperative staging and thus cannot be significant criteria foe decision-making about operative treatment modalities.

Reginal Lymph Node Involvement is Associated With Poorer Survivorship in Patients With Malignant Bone Tumor

Background Regional lymph node involvement is rare in patients with malignant bone tumors. We aimed to analyze the prevalence and prognostic implications in the lymph-involved patients with malignant bone tumors. Materials and Methods From 1988 to 2016, 9582 patients with primary malignant bone tumors in the SEER database were enrolled. Overall survival (OS) was computed using the Kaplan-Meier method. A multivariate analysis was performed using the Cox regression. Results 346 (3.63%) patients exhibited regional lymph node involvement. Lymph-involved patients had larger tumor size and more metastasis than patients without. Ewing sarcoma most frequently developed lymph node involvement. Lymph-involved patients (0.31 95% CI (0.26–0.37)) had lower 5-year OS rates than patients without lymph node involvement (0.66 95% CI (0.65–0.68)) (p<0.001). Conclusions Lymph node involvement is rare in patients with malignant bone tumors. They had a large tumor size, more distant metastasis and poor survival.